{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:47Z","timestamp":1791489587863,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":223,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ck0106825h0001"],"award-info":[{"award-number":["23ck0106825h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101378","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:48:37Z","timestamp":1787248117000},"page":"101378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Financial burden of immune checkpoint inhibitor maintenance therapy in Japan: a real-world cost analysis from an academic medical center"],"prefix":"10.1016","volume":"49","author":[{"given":"Shinji","family":"Tamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9178-790X","authenticated-orcid":false,"given":"Satoshi S.","family":"Nishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ctarc.2026.101378_bib0002","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jjco\/hyad085","article-title":"Clinical development of immune checkpoint inhibitors in Japan-the same goal, different paths","volume":"53","author":"Sekine","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101378_bib0003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101378_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101378_bib0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/bcp.14337","article-title":"Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapy","volume":"86","author":"Kim","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101378_bib0006","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jamainternmed.2020.4793","article-title":"Drug reimbursement regulation in 6 peer countries","volume":"180","author":"Emanuel","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101378_bib0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101378_bib0008","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamaoncol.2021.7987","article-title":"Financial Toxicity of cancer treatment","volume":"8","author":"Hussaini","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101378_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.983581","article-title":"What is the optimal duration of immune checkpoint inhibitors in malignant tumors?","volume":"13","author":"Yin","year":"2022","journal-title":"Front. Immunol."},{"issue":"33","key":"10.1016\/j.ctarc.2026.101378_bib0010","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101378_bib0011","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101378_bib0012","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1158\/1078-0432.CCR-19-3418","article-title":"Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC","volume":"26","author":"Hellmann","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101378_bib0013","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101378_bib0014","doi-asserted-by":"crossref","first-page":"eabi8618","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101378_bib0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2020.09.035","article-title":"Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital polymerase chain reaction","volume":"160","author":"Iwaya","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101378_bib0016","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41416-021-01266-4","article-title":"Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling","volume":"124","author":"Yaegashi","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101378_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jmoldx.2024.01.006","article-title":"The clinical validity of urinary pellet DNA monitoring for the diagnosis of recurrent bladder cancer","volume":"26","author":"Abe","year":"2024","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101378_bib0018","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cas.16446","article-title":"Comprehensive genome profiling-initiated tumor-informed circulating tumor DNA monitoring for patients with advanced cancer","volume":"116","author":"Sasaki","year":"2025","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101378_bib0019","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1097\/AS9.0000000000000549","article-title":"Impact of sensitive circulating tumor DNA monitoring on CT scan intervals during postoperative colorectal cancer surveillance","volume":"6","author":"Sasaki","year":"2025","journal-title":"Ann. Surg. Open"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101378_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cas.16025","article-title":"Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma","volume":"115","author":"Tamura","year":"2024","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101378_bib0021","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jjco\/hyaa054","article-title":"A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study)","volume":"50","author":"Nomura","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101378_bib0022","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","article-title":"Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials","volume":"31","author":"Niraula","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101378_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.47950","article-title":"Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia","volume":"6","author":"Winn","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101378_bib0024","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2012positive, advanced non\u2012small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101378_bib0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101378_bib0026","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101378_bib0027","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm","volume":"17","author":"Robert","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.ctarc.2026.101378_bib0028","article-title":"Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA non-small-cell lung cancer (NSCLC): a phase II multicenter exploratory study \u2014 final data of patients who underwent surgical assessment","volume":"37","author":"Provencio","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101378_bib0029","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101378_bib0030","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101378_bib0031","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cmp.2025.06.002","article-title":"Intra-tumor DKK1 and CALML5 heterogeneity as a novel biomarker for prognosis and immunotherapy response in head and neck squamous cell carcinoma","volume":"18","author":"Li","year":"2025","journal-title":"Curr. Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101378_bib0032","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41401-020-0400-z","article-title":"Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy","volume":"41","author":"Gao","year":"2020","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:38:34Z","timestamp":1791488314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"alternative-id":["S2468294226002893"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101378","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial burden of immune checkpoint inhibitor maintenance therapy in Japan: a real-world cost analysis from an academic medical center","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101378"}}